International Scientific Conference to Focus on Emerging Infectious Diseases and Antimicrobial Resistance in Asia
- S.-Japan Cooperative Medical Sciences Program’s (USJCMSP) 19th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim runs from Feb. 7 to 10
- First time conference held in South Korea; the International Vaccine Institute is the local host
February 7, 2017, Seoul, Korea – The “U.S.-Japan Cooperative Medical Sciences Program (USJCMSP) 19th International Conference on Emerging Infectious Diseases (EID) in the Pacific Rim” kicked off its first day at the Novotel Ambassador Seoul Gangnam. Held for the first time in South Korea, the International Vaccine Institute (IVI) is the local host of the four-day conference, which runs from February 7-10.
Since 1996, the United States-Japan Cooperative Medical Sciences Program has been convening the EID conference annually in alternating countries. It serves as a venue for panel meetings and discussion of cross-cutting topics related to infectious disease research to promote international cooperation in research efforts in response to new, emerging infectious disease challenges of Asia and the greater Pacific region.
The conference draws researchers, government and public health officials, and representatives from academia and other public and private institutions from Pacific Rim countries such as South Korea and Japan, and the United States. More than 300 people from over 20 countries are participating this year, and speakers include researchers from the National Institute of Allergy and Infectious Diseases (NIAID), USA; Yonsei University; National Cancer Center, Korea; Harvard University; Hokkaido University Research Center for Zoonosis Control, Japan; China Agricultural University; and National Institute of Infectious Diseases (NIID), Japan among many others.
This year’s conference focuses on antimicrobial resistance of bacterial and parasitic diseases of importance in the Asia-Pacific region. In addition, panels on Acute Respiratory Infections (ARI), Cancer, Cholera and Other Bacterial Enteric Infections, Mycobacteria, and Parasitic Diseases present the latest research in these disease areas. Oral and poster presentations will be given at the conference and disease panel workshops over the four days.
“As the local host and co-sponsor this year, we are very pleased to be a part of this major international scientific conference in the Asia-Pacific region,” said Jerome Kim, IVI Director General, “The program features discussions and presentations by scientific experts from around the world who will share latest research findings related to antimicrobial resistance, a timely and pressing topic in global health.”
Among the speakers providing welcome remarks on the first day were Marc Knapper, Chargé d'Affaires, US Embassy in Seoul; Hideo Suzuki, Chargé d'Affaires ad interim, Embassy of Japan in Seoul; Jerome Kim, Director General of IVI; Aikichi Iwamoto, Science and Technology Advisor, Japan Agency for Medical Research and Development (AMED); and Patrick Brennan, University Distinguished Professor, Colorado State University
The conference was co-sponsored by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), the Japanese Ministries of Health, Labor and Welfare (MHLW) and Education, Culture, Sports, Science and Technology (MEXT), the Japan Agency for Medical Research and Development (AMED), and IVI. Support was also provided by the Bill & Melinda Gates Foundation.
The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, MERS-CoV, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.
Tae Kyung Byun
Phone: +82-2-872-2801 (Ext. 159)